Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives
Clinica Chimica Acta · 2023-03 · 543 · 117326
DOI: 10.1016/j.cca.2023.117326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinica Chimica Acta, 2023-03. Verfasst von Céline Narjoz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, INSER…. Hauptthemen laut MEDLINE: Dihydropyrimidine Dehydrogenase Deficiency, Renal Insufficiency, Chronic, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Pretherapeutic screening for dihydropyrimidine dehydrogenase (DPD) deficiency based on the measurement of plasma uracil ([U]) is recommended prior to the administration of fluoropyrimidine-based chemotherapy. Cancer patients frequently have impaired kidney function, but the extent to which kidney function decline impacts [U] levels has not been comprehensively investigated. METHODS: We assessed the relationship between DPD phenotypes and estimated glomerular filtration rate (eGFR) in 1751 patients who benefited on the same day from a screening for DPD deficiency by measuring [U] and [UH2]:[U], and an evaluation of eGFR. The impact of a kidney function decline on [U] levels and [UH2]:[U] ratio was evaluated. RESULTS: We observed that [U] was negatively correlated with eGFR, indicating that [U] levels increase as eGFR declines. For each ml/min of eGFR decrease, [U] value increased in average by 0.035 ng/ml. Using the KDIGO classification of chronic kidney disease (CKD), we observed that [U] values >16 ng/ml (DPD deficiency) were measured in 3.6 % and 4.4 % of stage 1 and 2 CKD (normal-high eGFR, >60 ml/min/1.73 m2) patients, but in 6.7 % of stage 3A CKD patients (45 to 59 ml/min/1.73 m2), 25% of stage 3B CKD patients (30 to 44 ml/min/1.73 m2), 22.7% of stage 4 CKD patients (15 to 29 ml/min/1.73 m2 and 26.7% of stage 5 CKD patients (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, INSERM UMRS1138, Centre de Recherche des Cordeliers, F-75006 Paris, France.
- Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris University, France.
- Department of Clinical Chemistry, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, INSERM UMRS1138, Centre de Recherche des Cordeliers, F-75006 Paris, France.…
Zitieren
APA
Narjoz, C., Nadour, Z., Zaanan, A., Taieb, J., Loriot, M. A., & Pallet, N. (2023). Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives. Clinica Chimica Acta, 543, 117326. https://doi.org/10.1016/j.cca.2023.117326
Vancouver
Narjoz C, Nadour Z, Zaanan A, Taieb J, Loriot MA, Pallet N. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives. Clinica Chimica Acta. 2023;543:117326. doi:10.1016/j.cca.2023.117326
BibTeX
@article{Narjoz2023,
author = {Narjoz, Céline and Nadour, Zahia and Zaanan, Aziz and Taieb, Julien and Loriot, Marie-Anne and Pallet, Nicolas},
title = {Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives},
journal = {Clinica Chimica Acta},
year = {2023},
volume = {543},
pages = {117326},
doi = {10.1016/j.cca.2023.117326}
}
EUVIMED